Dr. Schroeder on the Importance of JAK Inhibition in GVHD

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Mark A. Schroeder, MD, an associate professor at the Washington University School of Medicine in St. Louis, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

New therapies are emerging for patients with acute GVHD, such as JAK inhibitors, α-1 antitrypsin, and a novel agonist antibody called IL-22. JAK inhibition works by blocking cytokines, which are essential for stimulating GVHD response. JAK-STAT signaling is critical for immune cell development, says Schroeder. By blocking this signaling pathway with a JAK inhibitor, such as ruxolitinib (Jakafi) or itacitinib, you can block these essential signals, which are critical for T-cell proliferation.

A critical cytokine called interferon-gamma signals through JAK1/2. JAK1/2 inhibition prevents T cells from reaching the organs that are involved with GVHD, such as the gut, and other sites of GVHD, says Schroeder. Blocking interferon gamma or other cytokines decreases the inflammatory milieu of GVHD and effects the presentation of antigens in the stimulation of T cell response. Recently, other groups have shown that blocking interferon-gamma signaling, specifically in the gut, decreases damage to essential cells that regenerate the gut, concludes Schroeder.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.